UY38550A - NLRP3 FLAMASOMA INHIBITING COMPOUNDS, COMPOSITIONS, COMBINATIONS AND RELATED METHODS - Google Patents
NLRP3 FLAMASOMA INHIBITING COMPOUNDS, COMPOSITIONS, COMBINATIONS AND RELATED METHODSInfo
- Publication number
- UY38550A UY38550A UY0001038550A UY38550A UY38550A UY 38550 A UY38550 A UY 38550A UY 0001038550 A UY0001038550 A UY 0001038550A UY 38550 A UY38550 A UY 38550A UY 38550 A UY38550 A UY 38550A
- Authority
- UY
- Uruguay
- Prior art keywords
- nlrp3
- compositions
- flamasoma
- combinations
- related methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D513/14—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invención se refiere a nuevos compuestos de tienopirrolotriazinacetamida de la fórmula (I): en donde R1, R2 y R3 se definen en el presente documento, que inhiben la actividad inflamatoria de la proteína 3 receptora de tipo NOD (NLRP3). La invención se refiere, además, a los procesos para su preparación, composiciones farmacéuticas y medicamentos que los contienen, y su uso en el tratamiento de enfermedades y trastornos mediados por NLRP3.The present invention relates to new thienopyrrolotriazineacetamide compounds of formula (I): wherein R1, R2 and R3 are defined herein, which inhibit the inflammatory activity of NOD-like receptor protein 3 (NLRP3). The invention further relates to the processes for their preparation, pharmaceutical compositions and drugs containing them, and their use in the treatment of diseases and disorders mediated by NLRP3.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19175246 | 2019-05-17 | ||
| PCT/IB2019/056278 WO2020021447A1 (en) | 2018-07-25 | 2019-07-23 | Nlrp3 inflammasome inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY38550A true UY38550A (en) | 2020-12-31 |
Family
ID=66685350
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY0001038550A UY38550A (en) | 2019-05-17 | 2020-01-22 | NLRP3 FLAMASOMA INHIBITING COMPOUNDS, COMPOSITIONS, COMBINATIONS AND RELATED METHODS |
Country Status (4)
| Country | Link |
|---|---|
| AR (1) | AR117863A1 (en) |
| EA (1) | EA202190329A1 (en) |
| TW (1) | TW202110856A (en) |
| UY (1) | UY38550A (en) |
-
2019
- 2019-07-23 EA EA202190329A patent/EA202190329A1/en unknown
-
2020
- 2020-01-22 TW TW109102478A patent/TW202110856A/en unknown
- 2020-01-22 AR ARP200100158A patent/AR117863A1/en unknown
- 2020-01-22 UY UY0001038550A patent/UY38550A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AR117863A1 (en) | 2021-09-01 |
| EA202190329A1 (en) | 2021-05-18 |
| TW202110856A (en) | 2021-03-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2021000019A (en) | INFLAMASOME INHIBITORS NLRP3 | |
| CL2021003012A1 (en) | nlrp3 inflammasome inhibitors | |
| ECSP24014832A (en) | NLRP3 INHIBITORS | |
| DOP2021000183A (en) | CONDENSED TRICYCLIC COMPOUNDS USEFUL AS ANTI-CANCER AGENTS | |
| CO2019011762A2 (en) | Compounds that inhibit mcl-1 protein | |
| EA202091512A1 (en) | SULFONYLUREA DERIVATIVES AS NLRP3 INFLAMMASOM MODULATORS | |
| CO2018000344A2 (en) | 1,4-substituted piperidine derivatives | |
| BR112016028642A2 (en) | compound, pharmaceutical composition, method of treating a disease or condition, method of inhibiting the activity of a phosphatidylinositol 3-kinase polypeptide, method of inhibiting immune reactions or overgrowth or destructive cancer cell proliferation, kit, and, use of a compound, salt, isomer or a pharmaceutically acceptable mixture thereof. | |
| CL2013002690A1 (en) | Compounds derived from bis (fluoroalkyl) -1,4-benzodiazepinone, notch inhibitors; crystalline compound; pharmaceutical composition that includes them; pharmaceutical combination; and its use for the treatment of cancer. | |
| CL2022000201A1 (en) | akr1c3-dependent tricyclic inhibitors of kars | |
| ECSP13013024A (en) | 1,3-OXAZINES AS INHIBITORS OF BACE1 AND / OR BACE2 | |
| ECSP13013068A (en) | HALOGENOALQUIL-1,3-OXAZINAS AS INHIBITORS OF THE BACE1 AND / OR BACE2 | |
| BR112016028818A2 (en) | pharmaceutical composition, methods of treating a disease or condition, inhibiting the activity of a phosphatidylinositol 3-kinase polypeptide and inhibiting excessive or destructive immune reactions or cancer cell growth or proliferation, kit, compound, salt, isomer, or a pharmaceutically acceptable mixture thereof, and, use of a compound, a salt, isomer, or a pharmaceutically acceptable mixture thereof. | |
| EA201990388A1 (en) | CXCR7 PIPERIDINE MODULATORS | |
| BR112016028814A2 (en) | pharmaceutical composition, methods of treating a disease or condition, inhibiting immune reactions or overgrowth or destructive cancer cell proliferation, kit, compound, a salt, an isomer, or a pharmaceutically acceptable mixture thereof, and, use of a compound, a salt, an isomer, or a pharmaceutically acceptable mixture thereof? | |
| UY33655A (en) | CCR30 CO-CRYSTALS AND SALES OF INHIBITORS | |
| UY38625A (en) | COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER | |
| BR112021011325A2 (en) | Rapamycin derivatives | |
| MX2020011405A (en) | Benzimidazole derivatives as modulators of retinoid-related orphan receptor gamma (rorï) and pharmaceutical uses thereof. | |
| CR20170513A (en) | USEFUL PIRAZOL DERIVATIVES AS INHIBITORS OF 5-LI-POXIGENASA ACTIVATING PROTEIN (FLAP). | |
| UY37729A (en) | NEW COMPOUNDS THAT INHIBIT THE ACTIVITY OF Nav1.7 | |
| CO2022012884A2 (en) | Fused Amino Pyrimidine Compounds | |
| AR117844A1 (en) | THIAZOLOPYRIDINE DERIVATIVES AS ANTAGONISTS OF THE ADENOSINE RECEPTOR | |
| BR112019024804A2 (en) | 5,6-fused bicyclic compounds and compositions for the treatment of parasitic diseases | |
| CO2021001174A2 (en) | Ckd8 / 19 inhibitors |